Pub. Date : 2021 Dec
PMID : 33931884
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, Tolerability, Pharmacokinetics, and Target Engagement. | 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide | FSHMD1A | Homo sapiens |
| 2 | AIMS: Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). | 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide | FSHMD1A | Homo sapiens |
| 3 | This study supports advancing losmapimod into Phase 2 trials in FSHD. | 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide | FSHMD1A | Homo sapiens |